2022 Fall Clinical Virtual Grand Rounds
2022 Virtual Grand Rounds Session 19: October 5, 2022
About
The Fall Clinical Virtual Grand Rounds returns with our 2022 new series. FCVGR consists of weekly CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology.
Please join us for this week's session:
Wednesday, October 5, 2022
8 PM ET/ 5 PM PT
What's New in Melanoma Therapeutics
Random Rashes
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
October 5, 2022
October 5, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Review the MOA of relatlimab, the most recently approved monoclonal antibody to treat melanoma
Recognize newly described and unusual cutaneous immune-related adverse events (irAEs), in addition to the four major groups of cutaneous irAEs
Review multiple presentations of and expand your differential for common conditions
Review medication adverse events and mechanisms
Intended Audience
Faculty
Jean Bolognia, MD
Professor of Dermatology
Vice Chair, Clinical Affairs
Yale School of Medicine
New Haven, CT
Daniela Kroshinsky, MD, MPH
Director of Inpatient Dermatology
Director of Pediatric Dermatology
Massachusetts General Hospital
Boston, MA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.